LONDON (Reuters) - The Pfizer-BioNTech COVID-19 vaccine may be less able to protect against infection with a South African variant of the virus that has a worrying mutation, according to results of a British study released on Tuesday.
Shannon Romano, a molecular biologist, came down with Covid late last March, about a week after she and her colleagues shut down their lab at Mount Sinai Hospital. A debilitating headache came first, followed by a fever that kept rising, and then excruciating body aches. “I couldn’t sleep. I couldn’t move,” she said. “Every one of my joints just hurt inside.”
It was not an experience she wanted to repeat — ever. So when she became eligible for the Covid-19 vaccine earlier this month, she got the shot.
A little more than a third of nursing home workers have been getting COVID-19 vaccines when the shots are first offered, U.S. health officials said Monday.
Recent Comments